AbbVie (ABBV) confirms it is to acquire Apogee Therapeutics (APGE)

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

[MARKET UPDATE]: Geopolitical risk-on trade seen as VP Vance speaks; equities, spot gold, and Treasuries gain with Dollar and oil sold

US VP Vance on Iran talks, says made a lot of progress; Strait is open; Want to make sure have proper coordination; Iranians have agreed to invite IAEA inspectors back

AbbVie (ABBV) confirms it is to acquire Apogee Therapeutics (APGE)

US VP Vance to speak in Switzerland at 12:00BST/07:00EDT

Merck (MRK) said the study met its primary endpoint of clinical remission according to the Modified Mayo Score at week 12, as well as key secondary endpoints

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for USD 135.11/shr in cash. 
  • The transaction values Apogee at a total equity value of approximately USD 10.9bln. 
  • The boards of directors of both companies have unanimously approved the transaction. 
  • This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.

Related headlines

The whole workspace, free to try.

Try it free